Table 3. Results of univariate and multivariate analyses evaluating the clinical and electrodiagnostic factors associated with MuSK MG compared to DSN MG.
| Variable | Univariate logistic regression | Multivariate logistic regression | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Age at onset | 0.995 | 0.954–1.037 | 0.801 | |||
| Sex, female | 5.359 | 1.499–19.418 | 0.010 | 1.655 | 0.350–7.826 | 1.655 |
| MGFA “b” at time of RNS | 8.889 | 3.038–26.006 | <0.001 | 6.410 | 1.892–21.718 | 0.003 |
| Disease severity at time of RNS | ||||||
| MGFA II+III | Reference | Reference | ||||
| MGFA IV+V | 6.750 | 1.412–32.262 | 0.017 | 3.466 | 0.575–20.897 | 0.175 |
| Abnormal RNS response in the face and normal RNS response in limbs | 9.375 | 2.789–31.512 | <0.001 | 5.224 | 1.300–20.990 | 0.020 |
| Immunosuppressive treatment before RNS | 1.624 | 0.607–4.346 | 0.334 | |||
CI: confidence interval, DSN: double-seronegative, MG: myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, MuSK: muscle-specific tyrosine kinase, OR: odds ratio, RNS: repetitive nerve stimulation.